Stabilization of the nitric oxide (NO) prodrugs and anticancer leads, PABA/NO and double JS-K, through incorporation into PEG-protected nanoparticles

Molecular Pharmaceutics

Volumn 7, Issue 1, 2010, Pages 291-298

  Kumar, Varun ^a   Hong, Sam Y ^b   Maciag, Anna E ^c   Saavedra, Joseph E ^c   Adamson, Douglas H ^d   Prud'homme, Robert K ^a   Keefer, Larry K ^b   Chakrapani, Harinath ^d,e  

^a Princeton University   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

Formulation; Glutathione; Glutathione S transferase; Nanoparticles; Nitric oxide; PABA NO

Indexed keywords

1,5 BIS [1 [(4 ETHOXYCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOL 2ATO]2,4 DINITROBENZENE; ANTINEOPLASTIC AGENT; COPOLYMER; GLUTATHIONE; LEAD; MACROGOL; NANOPARTICLE; NITRIC OXIDE; O2 [2,4 DINITRO 5 [(4 (N METHYLAMINO)BENZOYLOXY)PHENYL] 1 (N,N DIMETHYLAMINO)DIAZEN 1 IUM 1,2 DIOLATE]; POLYLACTIDE; POLYMER; POLYSTYRENE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DECOMPOSITION; DELAYED RELEASE FORMULATION; DOSE TIME EFFECT RELATION; DRUG ACTIVATION; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; HUMAN; HUMAN CELL; IC 50; KINETICS; PARTICLE SIZE; PRECIPITATION; PRIORITY JOURNAL; PROTEIN TARGETING; THERAPY EFFECT;

4-AMINOBENZOIC ACID; ANTINEOPLASTIC AGENTS; AZO COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; HUMANS; NANOPARTICLES; NITRIC OXIDE DONORS; PARTICLE SIZE; PIPERAZINES; POLYETHYLENE GLYCOLS; PRODRUGS;

EID: 76249127167     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900245h     Document Type: Article

References (47)

1. Furchgott, R. F. Endothelium-Derived Relaxing Factor: Discovery, Early Studies, and Identifcation as Nitric Oxide (Nobel Lecture). Angew. Chem., Int. Ed. 1999, 38, 1870-1880.
2. Ignarro, L. J. Nitric Oxide: A Unique Endogenous Signaling Molecule in Vascular Biology (Nobel Lecture). Angew. Chem., Int. Ed. 1999, 38, 1882-1892.
3. Murad, F. Discovery of Some of the Biological Effects of Nitric Oxide and Its Role in Cell Signaling (Nobel Lecture). Angew. Chem., Int. Ed. 1999, 38, 1856-1868.
4. Keefer, L. K. Nitric Oxide (NO)- and Nitroxyl (HNO)-generating Diazeniumdiolates (NONOates): Emerging Commercial Opportunities. Curr. Top Med. Chem. 2005, 5, 625-636.
5. Maciag, A.; Saavedra, J.; Chakrapani, H. The Nitric Oxide Prodrug JS-K and Its Structural Analogues as Cancer Therapeutic Agents. Anticancer Agents Med. Chem. 2009, 9, 798-803.
6. Kitagaki, J.; Yang, Y.; Saavedra, J. E.; Colburn, N.; Keefer, L. K.; Perantoni, A. O. Nitric Oxide Prodrug JS-K Inhibits Ubiquitin E1 and Kills Tumor Cells Retaining Wild-type p53. Oncogene 2009, 28, 619-624.
7. Simeone, A.-M.; McMurtry, V.; Nieves-Alicea, R.; Saavedra, J.; Keefer, L.; Johnson, M.; Tari, A. TIMP-2 Mediates the Anti-invasive Effects of the Nitric Oxide-releasing Prodrug JS-K in Breast Cancer Cells. Breast Cancer Res. 2008, 10, R44.
8. Chakrapani, H.; Kalathur, R. C.; Maciag, A. E.; Citro, M. L.; Ji, X.; Keefer, L. K.; Saavedra, J. E. Synthesis, Mechanistic Studies, and Anti-proliferative Activity of Glutathione/glutathione S-transferase-activated Nitric Oxide Prodrugs. Bioorg. Med. Chem. 2008, 16, 9764-9771.
9. . (9) Chakrapani, H.; Goodblatt, M. M.; Udupi, V.; Malaviya, S.; Shami, P. J.; Keefer, L. K.; Saavedra, J. E. Synthesis and in vitro Anti-leukemic Activity of Structural Analogues of JS-K, an Anti-cancer Lead Compound. Bioorg. Med. Chem. Lett. 2008, 18, 950-953.
10. Kiziltepe, T.; Hideshima, T.; Ishitsuka, K.; Ocio, E. M.; Raje, N.; Catley, L.; Li, C.-Q.; Trudel, L. J.; Yasui, H.; Vallet, S.; Kutok, J. L.; Chauhan, D.; Mitsiades, C. S.; Saavedra, J. E.; Wogan, G. N.; Keefer, L. K.; Shami, P. J.; Anderson, K. C. JS-K, a GST-activated Nitric Oxide Generator, Induces DNA Double-strand Breaks, Activates DNA Damage Response Pathways, and Induces Apoptosis in vitro and in vivo in Human Multiple Myeloma Cells. Blood 2007, 110, 709-718.
11. Udupi, V.; Yu, M.; Malaviya, S.; Saavedra, J. E.; Shami, P. J. JS-K, A Nitric Oxide Prodrug, Induces Cytochrome c Release and Caspase Activation in HL-60 Myeloid Leukemia Cells. Leuk. Res. 2006, 30, 1279-1283.
12. Shami, P. J.; Saavedra, J. E.; Bonifant, C. L.; Chu, J.; Udupi, V.; Malaviya, S.; Carr, B. I.; Kar, S.; Wang, M.; Jia, L.; Ji, X.; Keefer, L. K. Antitumor Activity of JS-K [O2-(2,4-Dinitrophenyl) 1-[(4-Ethoxycarbonyl) piperazin-1-yl]diazen-1-ium-1,2-diolate] and Related O2-Aryl Diazeniumdiolates in Vitro and in Vivo. J. Med. Chem. 2006, 49, 4356-4366.
13. Liu, J.; Li, C.; Qu, W.; Leslie, E.; Bonifant, C. L.; Buzard, G. S.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P. Nitric Oxide Prodrugs and Metallochemotherapeutics: JS-K and CB-3-100 Enhance Arsenic and Cisplatin Cytolethality by Increasing Cellular Accumulation. Mol. Cancer Ther. 2004, 3, 709-714.
14. Shami, P. J.; Saavedra, J. E.; Wang, L. Y.; Bonifant, C. L.; Diwan, B. A.; Singh, S. V.; Gu, Y.; Fox, S. D.; Buzard, G. S.; Citro, M. L.; Waterhouse, D. J.; Davies, K. M.; Ji, X.; Keefer, L. K. JS-K, a Glutathione/Glutathione S-Transferase-activated Nitric Oxide Donor of the Diazeniumdiolate Class with Potent Antine-oplastic Activity1. Mol. Cancer Ther. 2003, 2, 409-417.
15. Ren, Z.; Kar, S.; Wang, Z.; Wang, M.; Saavedra, J. E.; Carr, B. I. JS-K, A Novel Non-ionic Diazeniumdiolate Derivative, Inhibits Hep 3B Hepatoma Cell Growth and Induces c-Jun Phosphorylation via Multiple MAP Kinase Pathways. J. Cell. Physiol. 2003, 197, 426-434.
16. Townsend, D. M.; Manevich, Y.; He, L.; Hutchens, S.; Pazoles, C. J.; Tew, K. D. Novel Role for Glutathione S-Transferase {pi}: Regulator of Protein S-Glutathionylation Following Oxidative And Nitrosative Stress. J. Biol. Chem. 2009, 284, 436-445.
17. Andrei, D.; Maciag, A.; Chakrapani, H.; Citro, M. L.; Keefer, L. K.; Saavedra, J. E. Aryl Bis(diazeniumdiolates): Potent Inducers of S-Glutathionylation of Cellular Proteins and Their in Vitro Antiproliferative Activities. J. Med. Chem. 2008, 51, 7944-7952.
18. Townsend, D. M.; Findlay, V. J.; Fazilev, F.; Ogle, M.; Fraser, J.; Saavedra, J. E.; Ji, X.; Keefer, L. K.; Tew, K. D. A Glutathione S-Transferase {pi}-Activated Prodrug Causes Kinase Activation Concurrent with S-Glutathionylation of Proteins. Mol. Pharmacol. 2006, 69, 501-508.
19. Saavedra, J. E.; Srinivasan, A.; Buzard, G. S.; Davies, K. M.; Waterhouse, D. J.; Inami, K.; Wilde, T. C.; Citro, M. L.; Cuellar, M.; Deschamps, J. R.; Parrish, D.; Shami, P. J.; Findlay, V. J.; Townsend, D. M.; Tew, K. D.; Singh, S.; Jia, L.; Ji, X.; Keefer, L. K. PABA/NO as an Anticancer Lead: Analogue Synthesis, Structure Revision, Solution Chemistry, Reactivity toward Glutathione, and in Vitro Activity. J. Med. Chem. 2006, 49, 1157-1164.
20. Findlay, V. J.; Townsend, D. M.; Morris, T. E.; Fraser, J. P.; He, L.; Tew, K. D. A Novel Role for Human Sulfiredoxin in the Reversal of Glutathionylation. Cancer Res. 2006, 66, 6800-6806.
21. Findlay, V. J.; Townsend, D. M.; Saavedra, J. E.; Buzard, G. S.; Citro, M. L.; Keefer, L. K.; Ji, X.; Tew, K. D. Tumor Cell Responses to a Novel Glutathione S-Transferase-Activated Nitric Oxide-Releasing Prodrug. Mol. Pharmacol. 2004, 65, 1070-1079.
22. Chakrapani, H.; Wilde, T. C.; Citro, M. L.; Goodblatt, M. M.; Keefer, L. K.; Saavedra, J. E. Synthesis, Nitric Oxide Release, and Anti-leukemic Activity of Glutathione-activated Nitric Oxide Prodrugs: Structural Analogues of PABA/NO, an Anti-cancer Lead Compound. Bioorg. Med. Chem. 2008, 16, 2657-2664.
23. Allen, C.; Maysinger, D.; Eisenberg, A. Nano-engineering Block Copolymer Aggregates for Drug Delivery. Colloids Surf., B 1999, 16, 3-27.
24. Kumar, V.; Prud'homme, R. K. Thermodynamic Limits on Drug Loading in Nanoparticle Cores. J. Pharm. Sci. 2008, 97, 4904-4914.
25. Gref, R.; Minamitake, Y.; Peracchia, M.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable Long-circulating Polymeric Nanospheres. Science 1994, 263, 1600-1603.
26. Schoenmakers, R. G.; Wetering, P. v. d.; Elbert, D. L.; Hubbell, J. A. The Effect of the Linker on the Hydrolysis Rate of Drug-linked Ester Bonds. J. Controlled Release 2004, 95, 291-300.
27. Patri, A. K.; Kukowska-Latallo, J. F.; Baker, J. R. Targeted Drug Delivery with Dendrimers: Comparison of the Release Kinetics of Covalently Conjugated Drug and Non-covalent Drug Inclusion Complex. Adv. Drug Delivery Rev. 2005, 57, 2203-2214.
28. Kurtoglu, Y. E.; Navath, R. S.; Wang, B.; Kannan, S.; Romero, R.; Kannan, R. M. Poly(amidoamine) Dendrimer-drug Conjugates with Disulfide Linkages for Intracellular Drug Delivery. Biomaterials 2009, 30, 2112-2121.
29. Perumal, O.; Khandare, J.; Kolhe, P.; Kannan, S.; Lieh-Lai, M.; Kannan, R. M. Effects of Branching Architecture and Linker on the Activity of Hyperbranched Polymer-Drug Conjugates. Bioconjugate Chem. 2009, 20, 842-846.
30. Sengupta, S.; Eavarone, D.; Capila, I.; Zhao, G.; Watson, N.; Kiziltepe, T.; Sasisekharan, R. Temporal Targeting of Tumour Cells and Neovasculature with a Nanoscale Delivery System. Nature 2005, 436, 568-572.
31. Ansell, S. M.; Johnstone, S. A.; Tardi, P. G.; Lo, L.; Xie, S.; Shu, Y.; Harasym, T. O.; Harasym, N. L.; Williams, L.; Bermudes, D.; Liboiron, B. D.; Saad, W.; Prud'homme, R. K.; Mayer, L. D. Modulating the Therapeutic Activity of Nanoparticle Delivered Paclitaxel by Manipulating the Hydrophobicity of Prodrug Conjugates. J. Med. Chem. 2008, 51, 3288-3296.
32. NAr reactions. J. Org. Chem. 2001, 66, 3090-3098.
33. Hillmyer, M. A.; Bates, F. S. Synthesis and Characterization of Model Polyalkane-Poly(ethylene oxide) Block Copolymers. Macromolecules 1996, 29, 6994-7002.
34. Gindy, M. E.; Ji, S.; Hoye, T. R.; Panagiotopoulos, A. Z.; Prud'homme, R. K. Preparation of Poly(ethylene glycol) Protected Nanoparticles with Variable Bioconjugate Ligand Density. Biomacromolecules 2008, 9, 2705-2711.
35. Gindy, M. E.; Panagiotopoulos, A. Z.; Prud'homme, R. K. Composite Block Copolymer Stabilized Nanoparticles: Simultaneous Encapsulation of Organic Actives and Inorganic Nanostructures. Langmuir 2008, 24, 83-90.
36. Johnson, B. K.; Prud'homme, R. K. Chemical Processing and Micromixing in Confined Impinging Jets. AIChE J. 2003, 49, 2264-2282.
37. Liu, Y.; Cheng, C.; Liu, Y.; Prud'homme, R. K.; Fox, R. O. Mixing in a Multi-inlet Vortex Mixer (MIVM) for Flash Nanoprecipitation. Chem. Eng. Sci. 2008, 63, 2829-2842.
38. Akbulut, M.; Ginart, P.; Gindy, M. E.; Theriault, C.; Chin, K. H.; Soboyejo, W.; Prud'homme, R. K. Generic Method of Preparing Multifunctional Fluorescent Nanoparticles Using Flash NanoPrecipitation. Adv. Funct. Mater. 2009, 19, 718-725.
39. Liu, Y.; Kathan, K.; Saad, W.; Prud'homme, R. K. Ostwald Ripening of Beta-Carotene Nanoparticles. Phys. Rev. Lett. 2007, 98, 036102.
40. Kumar, V.; Wang, L.; Riebe, M.; Tung, H.; Prud'homme, R. K. Formulation and Stability of Itraconazole and Odanacatib Nanoparticles: Governing Physical Parameters. Mol. Pharmaceutics 2009, 6, 1118-1124.
41. Chen, T.; D'Addio, S. M.; Kennedy, M. T.; Swietlow, A.; Kevrekidis, I. G.; Panagiotopoulos, A. Z.; Prud'homme, R. K. Protected Peptide Nanoparticles: Experiments and Brownian Dynamics Simulations of the Energetics of Assembly. Nano Lett. 2009, 9, 2218-2222.
42. Molinspiration Cheminformatics, Bratislava, Slovak Republic, http://www.molinspiration.com/services/properties.html. Accessed on June 20, 2009.
43. Liu, J.; Xiao, Y.; Allen, C. Polymer-drug Compatibility: A Guide to the Development of Delivery Systems for the Anticancer Agent, Ellipticine. J. Pharm. Sci. 2004, 93, 132-143.
44. Daniels, A. U.; Chang, M. K. O.; Andriano, K. P.; Heller, J. Mechanical Properties of Biodegradable Polymers and Composites Proposed for Internal Fixation of Bone. J. Appl. Biomater. 1990, 1, 57-78.
45. Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res. 1986, 46, 6387-6392.
46. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Delivery Rev. 1991, 6, 181-202.
47. Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Controlled Release 2001, 74, 47-61.